DENDREON

Welcome to the Brand page for “DENDREON”, which is offered here for The mark consists of the term dendreon having a capital d and lowercase endreon in combination with a design element, the design element consisting of two discrete parts located above the adjacent letters e, o, and n, the first part being a feather shape having two pointed ends, the upper side of which is formed by a convex arc, and the lower side of which is formed by an elongated sine wave shape, resulting in the left side of the feather being thin and quill-shaped, and the right side of the feather being wider and rounder, the whole of the feather-shaped first part extending from the left side of the e slightly upward to the right side of the o; and the second part of the design element consisting of the x-axis mirror image of the first part, located to its right, such that the upper side of the feather-shaped second part is formed by an elongated cosine wave shape and the lower side is formed by a concave arc, with the whole of the feather-shaped second part extending from the left side of the o slightly upward to the right side of the n, resulting in the right half of the feather-shaped first part overlapping with the left half of the feather-shaped second part.;antibacterial pharmaceuticals; antibacterial substances for medical purposes; cells for medical or clinical use; chemical preparations for pharmaceutical or medical purposes, for cancer, infectious diseases, autoimmune diseases, allergies, and genetically induced conditions; intravenous bags sold filled with sipuleucel-t; pharmaceutical preparations for the treatment and prevention of cancer, infectious diseases, autoimmune diseases, allergies, and genetically induced conditions; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cancer, infectious diseases, autoimmune diseases, allergies, and genetically induced conditions; pharmaceutical preparations for cancer, infectious diseases, autoimmune diseases, allergies, and genetically induced conditions; pharmaceutical preparations, antivirals; pharmaceutical products for the treatment of cancer; pharmaceuticals, anti-infectives; therapeutic pharmaceutical for the treatment of cancer, infectious diseases, autoimmune diseases, allergies, and genetically induced conditions; living cells for medical use; pharmaceutical preparations for the treatment of infectious diseases;.

Its status is currently believed to be active. Its class is unavailable. “DENDREON” is believed to be currently owned by “DENDREON PHARMACEUTICALS LLC”.